Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1638 1644 1675
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18393538 | NOVEL RECEPTORS FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION | Non-Final OA | The Regents of the University of California |
| 19317328 | T-CELL EXPANSION METHOD AND USES | Non-Final OA | NEOGAP THERAPEUTICS AB |
| 18021687 | B-CELL BASED IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | Non-Final OA | Northwestern University |
| 19083100 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL DYSFUNCTION | Final Rejection | Compass Point Group, LLC |
| 18625699 | METHODS FOR USING ENRICHED EXOSOMES AS A PLATFORM FOR MONITORING ORGAN STATUS | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18003922 | DUAL CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CCD99- AND CLEC12A-EXPRESSING CANCERS | Non-Final OA | H. Lee Moffitt Cancer Center and Research Institute Inc. |
| 16610681 | RAPID METHOD FOR THE CULTURE OF TUMOR INFILTRATING LYMPHOCYTES | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18133900 | DEVICE AND METHOD FOR OBTAINING IMMUNO-STIMULATORY ANTIGEN-PRESENTING CELLS | Non-Final OA | Yale University |
| 17858320 | NOVEL DOMINANT NEGATIVE FAS POLYPEPTIDES, CELLS COMPRISING THEREOF AND USES THEREOF | Final Rejection | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES |
| 18767925 | METHOD FOR PRODUCING AN ANTI-LAG-3 ANTIBODY | Final Rejection | Daiichi Sankyo Company, Limited |
| 18270436 | ANTIBODY-GUIDED PCSK9-MIMICKING IMMUNOGENS LACKING 9-RESIDUE SEQUENCE OVERLAP WITH HUMAN PROTEINS | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17276959 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18670211 | AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR) | Final Rejection | BAYLOR RESEARCH INSTITUTE |
| 17576597 | DENDRITIC CELL IMMUNOTHERAPY | Final Rejection | BAYLOR COLLEGE OF MEDICINE |
| 18026335 | EX VIVO EXPANSION OF REGULATORY T CELLS FOR SUPPRESSION OF GRAFT VERSUS HOST DISEASE | Non-Final OA | City of Hope |
| 18421039 | REGULATORY T CELL EPITOPES | Non-Final OA | EpiVax Inc. |
| 18527054 | AAV-MEDIATED EXPRESSION OF LONG-ACTING ANTI-CCR5 BINDING AGENTS FOR THE TREATMENT AND PREVENTION OF HIV | Non-Final OA | CytoDyn, Inc. |
| 18192743 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 17777550 | Hyperactive Dendritic Cells Enable Durable Adoptive Cell Transfer-Based Anti-Tumor Immunity | Final Rejection | Children's Medical Center Corporation |
| 17594401 | METHODS OF TREATING TUBERCULOSIS | Non-Final OA | LONZA SALES AG |
| 18280147 | RECOMBINANT VSV-SARS-COV-2 VACCINE | Final Rejection | Sumagen Canada Inc. |
| 17918244 | MERS-CoV VACCINE | Final Rejection | Sumagen Canada Inc. |
| 18548442 | TRIMERIC POLYPEPTIDES AND USES THEREOF IN THE TREATMENT OF CANCER | Non-Final OA | LEADARTIS, S.L. |
| 18277041 | PATIENT SELECTION FOR TREATMENT WITH DENDRITIC CELL VACCINATION | Non-Final OA | SCTbio a.s. |
| 17788833 | POLYPEPTIDES COMPRISING MUTATED FORMS OF HUMAN VEGF-A WITH REARRANGEMENTS OF DISULFIDE BONDS AND COMPOSITIONS CONTAINING SAME | Non-Final OA | Centro de Ingeniería Genética y Biotecnología |
| 18038818 | ANTIBODY AND TAXANE COMBINATION THERAPY | Final Rejection | BioNTech SE |
| 18265777 | ANTI-SIRPa ANTIBODY AND APPLICATION THEREOF | Non-Final OA | Bioray Pharmaceutical (Hangzhou) Co., Ltd. |
| 18031724 | ANTIBODIES TARGETING PSMA AND CD3 AND USES THEREOF | Final Rejection | Janux Therapeutics, Inc. |
| 18020441 | VETO CAR-T CELLS | Final Rejection | Ichilov Tech Ltd. |
| 18246194 | TUMOR COMPLEX ANTIGEN, MULTIVALENT DENDRITIC CELL (DC) VACCINE, AND USE THEREOF | Non-Final OA | KOUSAI Bio Co., Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy